Pharmacokinetic aspects of oral etoposide;Pharmakokinetische aspekte der oralen applikation von etoposid

Klinische Padiatrie

Volumn 210, Issue 4, 1998, Pages 159-164

  Tillmann, Barbara ^a   Krümpelmann, Sebastian ^b   Würthwein, Gudrun ^a   Wagner, Alexandra ^a   Schulze Westhoff, Petra ^a   Hempel, Georg ^a   Jürgens, Herbert ^a   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Concentration interval; Etoposide; Interindividual variability; Oral chemotherapy; Pharmacokinetics

Indexed keywords

ETOPOSIDE; TROFOSFAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION;

EID: 0031830150     PISSN: 03008630     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1043872     Document Type: Article

References (27)

1. Boos, J., E. Real, P. Schulze-Westhoff, B. Pröbsting, H. Jürgens: Pharmakokinetik der Etoposid-Kurzinfusionen im Rahmen der GPOH-Therapieprotokolle. Klin. Pädiatr. 205 (1993) 288-294
2. Boos, J., S. Krümpelmann, P. Schulze-Westhoff, T. Euting, F. Berthold, H. Jürgens: Steady-State Levels and Bone Marrow Toxicity of Etoposide in Children and Infants: Does Etoposide Require Age-Dependent Dose Calculation? J. Clin. Oncol. 13 (1995) 2954-2960
3. Clark, P. I.: Clinical pharmacology and schedule dependency of the podophyllotoxin derivatives. Semin. Oncol. 19 (Suppl. 6) (1992) 20-27
4. Clark, P. I., M. L. Slevin, S. P. Joel, R. J. Osborne, D. I. Talbot, P. W. M. Johnson, R. Reznek, T. Masud, W. Gregory, P. F. M. Wrigley: A Randomized Trial of Two Etoposide Schedules in Small-Cell Lung Cancer: The Influence of Pharmacokinetics on Efficacy and Toxicity. J. Clin. Oncol. 12 (1994) 1427-1435
5. Crom, W. R., J. Mirro, T. Madden, W. P. Petros, J. K. Belt: Targeting plasma concentrations (Cp) of cancer Chemotherapy: Continuous infusion cytarabine (Ara-C) and Etoposide (VP-16) in the treatment of acute nonlymphocytic leukemia (ANLL). European J. Clin. Pharmacol. 36 (1989) A66
6. Gaast, A. van der, M. Vlastuin, T. C. Kok, T. A. W. Splinter: What is the Optimal Dose and Duration of Treatment With Etoposide? II. Comparative Pharmacokinetie Study of Three Schedules: 1 x 100 mg, 2 x 50 mg, and 4 x 25 mg of Oral Etoposide Daily for 21 Days. Semin. Oncol. 19 (1992) 8-12
7. Hande, K. R., M. G. Krozely, F. A. Greco, J. D. Hainsworth, D. H. Johnson: Bioavailability of Low-Dose Oral Etoposide. J. Clin. Oncol. 11 (1993) 374-377
8. Harvey, V. J., M. L. Slevin, S. P. Joel, A. Johnston, P. F. M. Wrigley: The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. Br. J. Cancer 52 (1985) 363-367
9. Heinzel, G., R. Woloszczak, P. Thomann: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC. Gustav Fischer Verlag, Stuttgart, Jena, New York, 1993
10. Hempel, G., S. Krümpelmann, A. May-Manke, B. Hohenlöchter, G. Blaschke, H. Jürgens, J. Roos: Pharmacokinetics of trofosfamide and its dechloroethylated metabolites. Cancer Chemother. Pharmacol. 40 (1997) 45-50
11. Jong, R. S. de, N. H. Mulder, D. R. A. Uges, S. Kaul, B. Winograd, D. Th. Sleijfer, H. J. M. Groen, P. H. B. Willemse, W. T. A. van der Graaf, E. G. E. de Vries: Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br. J. Cancer 75 (1997) 1660-1666
12. Katoli, O., H. Yamada, K Hiura, Y. Aoki, S. Kuroki: Clinical pharmacology and toxicity of low daily administration of oral etoposide in advanced lung cancer. J. Clin. Oncol. 31 (1941) 1155-1160
13. Liu, B., H. M. Earl, C. J. Poole, J. Dunn, D. J. Kerr: Etoposide protein binding in cancer patients. Cancer Chemother. Pharmacol. 36 (1995) 506-512
14. Lowis, S. P., D. R. Newell: Etoposide for the Treatment of Pediatric Tumours: What is the Best Way to Give It? Eur. J. Cancer 32A (1996) 2291-2297
15. Mathew, P., R. C. Ribeiro, D. Sonnichsen, M. Relling, C. Pratt, H. Mahmoud, L. Bowman, W. Meyer, L. Avery, W. Crist: Phase I Study of Oral Etoposide in Children With Refractory Solid Tumors. J. Clin. Oncol. 12 (1994) 1452-1457
16. Miller, A. A., C. F. Stewart, E. A. Tolley: Clinical pharmacodynamics of continous-infusion etoposide. Cancer Chemother. Pharmacol. 25 (1990) 361-366
17. Millward, M. J., D. R. Newell, K. Yuen, J. P. Matthews, K. Balmanno, C. J. Charlton, L. Gumbrell, M. J. Lind, F. Chapman, M. Proctor, D. Simmonds, B. M. J. Cantwell, A. H. Calvert: Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer. Cancer Chemother. Pharmacol. 37 (1995) 161-167
18. Minami, H., Y. Ando, S. Sakai, K. Shimokata: Clinical and Pharmacologic Analysis of Hyperfractionated Daily Oral Etoposide. J. Clin. Oncol. 13 (1995) 191-199
19. Nguyen L., E. Chatelut, Ch. Chevreau, B. Tranchand, I. Lochon, J-M. Bachaud, A. Pujol, G. Houin, R. Bugat, P. Canal: Population pharmacokinetics of total and unbound etoposide. Cancer Chemother. Pharmacol.41 (1998) 125-132
20. Pflüger, K. H., L. Schmidt, M. Merkel, H. Jungclas, K Havemann: Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother. Pharmacol. 20 (1987) 59-66
21. Ratain, M. J., R. Mick, R. L. Schilsky, N. J. Vogelzang, F. Berezin: Pharmacologically based dosing of etoposide: A means of safely increasing dose intensity. J.Clin. Oncol. 9 (1991) 1480-1486
22. Sessa, C., M. Zucchetti, V. Torri, O. Pagani, M. D'Incalci, D. Gentili, G. Martinelli, J. de Jong, M. Alerci, F. Cavalli: Chronic oral etoposide in small-cell lung cancer: Clinical and pharmacokinetic results. Ann. Oncol. 4 (1993) 553-558
23. Slevin, M. L., S. P. Joel, R. Whomsley, K. Devenport, V. J. Harvey, R. J. Osborne, P. F. M. Wrigley: The effect of dose on the bioavailability of oral etoposide: confirmation of a clinically relevant observation. Cancer Chemother. Pharmacol. 24 (1989) 329-331
24. Slevin, M. L., P. I. Clark, S. P. Joel, S. Malik, R. J. Osborne, W. M. Gregory, D. G. Lowe, R. H. Reznek, P. F. M. Wrigley: A Randomized Trial to Evaluate the Effect of Schedule on the Activity of Etoposide in Small-Cell Lung Cancer. J. Clin. Oncol. 7 (1989b) 1333-1340
25. Sonnichsen, D. S., R. C. Ribeiro, X. Luo, P. Mathew, M. V. Relling: Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors. Clin. Pharmacol. Ther. 58 (1995) 99-107
26. Stewart, C. F., J. A. Pieper, S. G. Arbuck, W. E. Evans: Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Ther. 45 (1989) 49-56
27. Tillmann, B., S. Krümpelmann, A. Wagner, P. Schulze-Westhoff, H. Jürgens, J. Boos: Pharmacological Aspects of the Oral Application of Etoposide. In: Hiddemann et al. (Hrsg.). Acute Leukemias. Bd. VII: Experimental Approaches and Novel Therapies. Springer-Verlag, Berlin, Heidelberg 1998